FAPI-74 PET/CT in Adults with Fibrosis

Phase

Condition

Scar Tissue

Treatment

[F-18]-FAPI-74

Clinical Study ID

NCT06413355

19923

853610

Ages > 21
All Genders

Study Summary

This protocol is intended as a basket protocol designed to evaluate the use of Fibroblast Activating Protein (FAP) PET/CT in imaging the presence of fibrosis caused by a variety of medical conditions where fibrosis is believed to lead to pathological effects and poor prognosis.

Eligibility Criteria

Inclusion

Inclusion Criteria (by cohort)

Head and Neck Cancer Cohort:

Participants will be ≥ 21 years of age
Diagnosis of oropharyngeal squamous cell carcinoma (OPSCC)
Determined to be surgical candidates
History of known or suspected fibrosis-inducing medical condition

PTLD Cohort:

Participants will be ≥ 21 years of age
Diagnosed with microbiologically confirmed DS-pTB (culture or PCR positive)
History of known or suspected fibrosis-inducing medical condition.
Patient-reported completion of TB treatment within 2 years of enrollment.

Cardiac Sarcoidosis Cohort:

Participants will be ≥ 21 years of age
FDG PET/CT scan consistent with metabolically active cardiac sarcoidosis
Clinical suspicion of cardiac involvement defined as the presence of any of the following:
High degree A-V nodal block
Reduced left or right ventricular systolic fusion
History of ventricular arrhythmias
Unexplained syncope

Exploratory Cohort:

Participants will be ≥ 21 years of age
History of known or suspected fibrosis-inducing medical condition.

All Cohorts:

Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria (by cohort)

Head and Neck Cancer Cohort:

Patient is not eligible for tissue resection

PTLD Cohort:

Diagnosed with TB that is resistant to rifampin per medical record review
History of alternative pulmonary disease per medical record review or patient self-report
Have been administered corticosteroids or any other systemic investigational agents within 3 months of screening per medical record review or patient self-report
Have symptoms or signs suggestive of active TB at the time of pre-screening per patient self-report

All Cohorts:

Women of childbearing potential may not be pregnant or breast-feeding. A negative pregnancy test will be required before [F-18]-FAPI-74injection.
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
Treatment with a therapeutic agent targeting fibroblast activation protein (FAP) within 1 month prior to study enrollment.

Study Design

[F-18]-FAPI-74

July 16, 2024

July 30, 2027

Study Description

A study to evaluate subjects with fibrosis-inducing medical conditions that are known or suspected to cause tissue fibrosis (e.g. cancer-associated, post-infection, post-radiation, pre or post-transplant, cardiac, liver, kidney or pulmonary fibrosis). This protocol is intended to expand as needed with imaging arms designed to evaluate the use of Fibroblast Activating Protein (FAP) PET/ CT in imaging the presence fibrosis caused by medical conditions where fibrosis is believed to lead to pathological effects and poor prognosis.

[18F]-FAPI-74 is a positron emitting radiolabeled FAP inhibitor that will be used with a positron emission tomography/computed tomography (PET/CT) scan that will be completed in each subject who has a clinical suspicion of fibrotic disease.

PET/CT imaging will be used to evaluate the distribution of fibroblast activating protein (FAP) in major organs and other tissues affected with fibrotic diseases or conditions. This is an observational study in that [F-18]-FAPI-74 PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [F-18]-FAPI-74 PET/CT results, any medical or treatment decisions related to their underlying clinical diagnosis will be made by the treating physicians based upon clinical criteria.

After injection of [F-18]-FAPI-74, patients will undergo a vertex to mid-thigh scan, starting at approximately 60 minutes post injection. PET/CT imaging sessions will include an injection of approximately 8.0 mCi (expected range of doses is expected to be 6.0-8.0 mCi) of [F-18]-FAPI-74 intravenously. Data will be collected to evaluate uptake of [F-18]-FAPI-74 in sites of suspected fibrosis and in major organs.

An optional second PET/CT using [F-18]-FAPI-74 can be considered at the request of the investigators at any clinically relevant time point for the H&N, Exploratory and Cardiac Sarcoidosis cohorts. This second scan may be used to quantify the changes in fibrosis over time as part of the natural progression of the fibrotic condition, or to observe changes in [F-18]-FAPI-74 uptake in response to therapeutic interventions.

Imaging cohorts include:

Head and neck cancer (up to 15 patients) Post tubercular lung disease (PTLD, up to 10 patients) Cardiac Sarcoidosis (up to 10 patients) Exploratory Cohort (Pilot studies for generating clinical data to support use of the radiotracer for FAP targeted therapies, up to 10 patients)

Uptake of [F-18]-FAPI-74 may be compared to other clinical pathology or lab results related to the presence of fibrosis (e.g. tissue sequencing, genomics, immunohistochemistry, ELISA, and similar assays))

Connect with a study center

University of Pennsylvania
Philadelphia, Pennsylvania 19104
United States
Active - Recruiting

+−

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.